Company Overview of Conatus Pharmaceuticals Inc.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
16745 West Bernardo Drive
San Diego, CA 92121
Founded in 2005
Key Executives for Conatus Pharmaceuticals Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $419.5K
Co-Founder, Chief Scientific Officer and Senior Vice President of Research & Development
Total Annual Compensation: $283.1K
Compensation as of Fiscal Year 2013.
Conatus Pharmaceuticals Inc. Key Developments
Conatus Pharmaceuticals Inc. Announces Clinical Results At EASL Meeting Support Emricasan Registration Pathway in NASH
Apr 23 15
Conatus Pharmaceuticals Inc. announced that posters providing detailed results from four recently completed clinical trials of emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, are being presented this week at The International Liver Congress™ 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 22-26, 2015. Results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with acute-on-chronic liver failure (ACLF), and Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH), are addressed in two late-breaker posters:
Poster #LP35, entitled A placebo-controlled, multicenter, double-blind, randomised, pharmacokinetic and pharmacodynamic trial of emricasan (IDN-6556) in subjects with acute-on-chronic liver failure (ACLF); and poster #LP37, entitled A placebo-controlled, multicenter, double-blind, randomised trial of emricasan (IDN-6556) in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases. A third poster addresses results from the company's Phase 1 trial in patients with mild, moderate and severe hepatic impairment and the company's Phase 1 trial in patients with severe renal impairment: Poster #P0396, entitled Emricasan, a potent pan-caspase inhibitor, rapidly reduces caspase activity and biomarkers of apoptosis in patients with hepatic impairment but not in healthy volunteers: implications for safety, selectivity and mechanism of action. The company intends to include NASH-driven cirrhosis in its initial registration strategy for emricasan. This population already represents a high unmet medical need that is expected to continue growing in the years ahead. Importantly, three validated surrogate markers of mortality risk were identified for this segment of liver disease patients in a manuscript co-authored by the American Association for the Study of Liver Diseases (AASLD) and the U.S. Food and Drug Administration (FDA), and accepted in January 2015 for publication in the scientific journal Hepatology: Model for End-stage Liver Disease (MELD) score; Child-Pugh-Turcotte (CPT) score; and Hepatic venous pressure gradient (HVPG).
Conatus Pharmaceuticals Announces Top-Line Results from Phase 2 Double-Blind, Placebo-Controlled Clinical Trial of Emricasan
Mar 26 15
On March 26, 2015, Conatus Pharmaceuticals Inc. announced top-line results from the Company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH). The trial met its primary endpoint, showing a statistically significant (p<0.05) reduction in alanine amino transferase (ALT) in patients treated for 28 days with emricasan at 25 mg twice per day dosing compared to patients in the placebo control group. Reductions from baseline in ALT at Day 28 of approximately 39% in the emricasan treatment arm and approximately 14% in the placebo arm were similar to results observed in previous trials. Elevated baseline levels of three key serum biomarkers caspase-cleaved cytokeratin 18 (cCK18), full length cytokeratin 18, and caspase 3/7 also showed statistically significant reductions from baseline in emricasan-treated patients at Day 28. The baseline elevation in cCK18 confirmed that the underlying targets of emricasan's mechanism, apoptosis and inflammation, which are believed to drive liver disease progression, were engaged in the NAFLD/NASH patients in this trial. A reduction from baseline in cCK18 at Day 28 of approximately 30% in the emricasan treatment arm and an increase from baseline of approximately 4% in the placebo arm were similar to results observed in previous trials. The reduction in serum cCK18 levels demonstrated that emricasan can effectively reduce inflammation and elevated levels of apoptosis in NAFLD/NASH patients. These results were consistent with data obtained from the Company's previous clinical trials in other liver disease patient populations.
Conatus Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM
Mar 25 15
Conatus Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|